Cargando…
A 21-Day of Adjunctive Corticosteroid Use May Not Be Necessary for HIV-1-Infected Pneumocystis Pneumonia with Moderate and Severe Disease
BACKGROUND: The current guidelines recommend 21-day adjunctive corticosteroid therapy for HIV-1-infected pneumocystis pneumonia patients (HIV-PCP) with moderate-to-severe disease. Whether shorter adjunctive corticosteroid therapy is feasible in such patients is unknown. METHODS: We conducted a retro...
Autores principales: | Shibata, Satoshi, Nishijima, Takeshi, Aoki, Takahiro, Tanabe, Yoshinari, Teruya, Katsuji, Kikuchi, Yoshimi, Kikuchi, Toshiaki, Oka, Shinichi, Gatanaga, Hiroyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578946/ https://www.ncbi.nlm.nih.gov/pubmed/26393804 http://dx.doi.org/10.1371/journal.pone.0138926 |
Ejemplares similares
-
High Mortality of Disseminated Non-Tuberculous Mycobacterial Infection in HIV-Infected Patients in the Antiretroviral Therapy Era
por: Kobayashi, Tetsuro, et al.
Publicado: (2016) -
Case report: new development of fibrosing interstitial lung disease triggered by HIV-related pneumocystis pneumonia
por: Suzuki, Tetsuya, et al.
Publicado: (2019) -
Cerebral Syphilitic Gumma within 5 Months of Syphilis in HIV-Infected Patient
por: Tsuboi, Motoyuki, et al.
Publicado: (2016) -
Preemptive Therapy Prevents Cytomegalovirus End-Organ Disease in Treatment-Naïve Patients with Advanced HIV-1 Infection in the HAART Era
por: Mizushima, Daisuke, et al.
Publicado: (2013) -
Is Ritonavir-Boosted Atazanavir a Risk for Cholelithiasis Compared to Other Protease Inhibitors?
por: Hamada, Yohei, et al.
Publicado: (2013)